ClouDr Group (9955) H2 2023 earnings summary

Executive summary

• FY2023 revenue rose 23.5% YoY to RMB3,690.5m; gross profit grew 14.8% to RMB909.4m, while adjusted net loss narrowed 77.4% to RMB75.1m.

• Growth was led by in-hospital operations and the new P2M product-sales model, supported by wider hospital and pharmacy SaaS networks.

Financial highlights

• Revenue was RMB3,690.5m, up 23.5% YoY; gross profit was RMB909.4m, up 14.8%.

• Gross margin fell to 24.6% from 26.5% as the revenue mix shifted toward lower-margin value-added solutions.

• Operating loss narrowed 46.9% to RMB314.2m; IFRS net loss narrowed 80.7% to RMB327.3m, partly reflecting no repeat of the prior-year fair-value loss on financial liabilities.

• Adjusted net loss, a non-IFRS measure, narrowed to RMB75.1m from RMB332.8m; adjusted net loss margin improved to 2.0% from 11.1%.

• Basic and diluted loss per share was RMB0.60, versus RMB5.62 in 2022.

Outlook and guidance

• Priorities include expanding hospital and pharmacy SaaS, building a proprietary-product pipeline under P2M, investing in medical AI, growing patient and doctor users, and pursuing strategic partnerships and acquisitions.

• Hospital plans center on the AIM model, deeper hospital relationships, wider SaaS installations, and monetization through targeted marketing and P2M products.

• Pharmacy plans include extending SaaS reach and services, enriching products and supply-chain capabilities, and expanding P2M to improve segment profitability.

• Individual-care operations will prioritize medical-service quality and organic, efficient growth in doctor and patient engagement; stronger monetization is expected from the ecosystem flywheel.